BioSpace News Archive

Sonendo, Inc. announced that, on November 15, 2023, it received a notice from the New York Stock Exchange that the Company was no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the Company’s average global market capitalization over a consecutive 30 trading-day period being less than $50 million and its stockholders’ equity being less than $50 million.

Baird Medical Devices, Inc. today announced that its subsidiary, Betters (Suzhou) Medical Co., Ltd, has received clearance from the U.S. Food and Drug Administration (the “FDA”) under Section 510 (K) to begin marketing its portfolio of Microwave Ablation Systems and Disposable Microwave Ablation Needles as regulatory Class II devices in the United States.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, has entered into an agreement to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil® (remestemcel-L) in the treatment of adults with steroid-refractory acute graft versus host disease (SR-aGvHD).

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET.

Asep Medical Holdings Inc. is very pleased to announce that, through its subsidiary Sepset Biosciences Inc., it has signed a definitive joint venture agreement with leading Chinese medical diagnostic company, Sansure Biotech Inc., through its subsidiary, Hunan Xiang Jiang Sansure Biotech Fund, L.P. Sansure Fund is an investment fund formed by Sansure, Changsha Sanway Spring Venture Capital CO., Ltd. and certain other investors.

Innovent Biologics, Inc. announces that full results from a Phase 2 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes were published in Diabetes Care.

Pharming Group N.V. announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, in children ages one to six years, with activated phosphoinositide 3-kinase delta syndrome.

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Hyrimoz® citrate-free high concentration formulation in Europe.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present at the SEB Annual Healthcare Seminar on Thursday, November 23, 2023, in Stockholm, Sweden.

Connect Biopharma Holdings Limited announced that two of its wholly owned subsidiaries, Connect Biopharma Hong Kong Limited and Suzhou Connect Biopharma Co., Ltd., have entered into an exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Ltd., to develop and commercialize Connect Biopharma’s rademikibart in Greater China.